Osteoarthritic Pain – Landscape & Forecast – Disease Landscape & Forecast

OA pain is the second largest segment of the overall chronic pain market, affecting more than 90 million patients in the G7. The OA pain market represents a lucrative opportunity for drug developers given the persistent unmet need for more effective and safe therapies, particularly those with a novel and distinct mechanism of action that strongly correlates with the nature of this type of pain. OA pain is predominantly treated with cost-effective generic NSAIDs and opioid analgesics, although branded agents such as costly abuse-deterrent reformulations of opioid analgesics, new combinations of existing NSAIDs that attempt to mitigate side effects, and intra-articular injections are also frequently prescribed in later lines of therapy. Emerging therapies, such as biological drugs from Pfizer / Eli Lilly and Regeneron / Teva / Mitsubishi Tanabe Pharma targeting NGF, and the increasing number of patients diagnosed with OA pain due to lifestyle influences will be key drivers for growth through 2028.

Questions answered:

  • How do interviewed experts perceive the OA pain marketplace to be changing given the emphasis on the risk of abuse / misuse with opioid analgesics?
  • What effect will the recent launches of new analgesics such as Flexion Therapeutics’ Zilretta and Iroko’s Vivlodex continue to have on the treatment paradigm?
  • What will the impact of a new drug class, the anti-NGF biologics, be on the treatment landscape given their demonstrably robust efficacy tempered by lingering concerns about safety issues seen in clinical trials?

Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: Thirteen country-specific interviews with thought-leading pain specialists and rheumatologists, supported by survey data collected for this and other DRG research.

Epidemiology: Diagnosed prevalence and drug-treated rates of OA pain by country.

Emerging therapies: Phase III / preregistration / registration: 8 drugs; Phase II: 7 drugs; coverage of select Phase I products.

Market forecast features: 10-year, annualized, drug-level sales and patient share of key analgesics through 2028, segmented by brands / generics.

Key companies: Acorda Therapeutics, Ampio Pharmaceuticals, Astellas, Centrexion, Collegium Pharmaceutical, Eli Lilly, Flexion Therapeutics, Iroko Pharmaceuticals, Mitsubishi Tanabe Pharma, Nektar Therapeutics, Pfizer, Purdue Pharma, Regeneron, Samumed, Teva.

Key drugs: acetaminophen / hydrocodone, Ampion, cebranopadol, celecoxib, CNTX-4975, fasinumab, Hysingla ER (hydrocodone ER), lorecivivint, Nucynta IR / ER (tapentadol IR / ER), oxycodegol (NKTR-181), oxycodone CR (OxyContin, generics), oxycodone ER (Xtampza ER), Qutenza (8% capsaicin patch), tanezumab, tramadol, Vivlodex (meloxicam, low dose), Zilretta (triamcinolone ER, injectable).

Product Description: Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents